Reaffirming revenue guidance, especially in a range that indicates growth, is generally viewed positively by investors as it reflects stability and confidence in the company's business model and market position. For Bionano Genomics, this announcement could bolster investor confidence, potentially leading to a positive short-term impact on its stock price.